Achilles therapeutics reports third quarter 2022 financial results and recent business highlights

- interim update from the ongoing phase i/iia trials in advanced nsclc (chiron) and melanoma (thetis) to be presented at the esmo immuno-oncology annual congress 2022 -

ACHL Ratings Summary

ACHL Quant Ranking